Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Remo Panaccione, Jordan Johns, Richard Moses, Joe Milata et al.
Citations
22 citations
Journal
Inflammatory Bowel Diseases
Topics
Inflammatory Bowel Disease
Field-Weighted Citation Impact (FWCI)
12.11
article
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Remo Panaccione, Jordan Johns, Richard Moses, Joe Milata, Bruce E. Sands, Severine A.R.A. Vermeire, Marla C. Dubinsky, Peter Miles Irving, David B. Clemow, Tadakazu Hisamatsu, Taku Kobayashi, Geert D’Haens, Scott D. Lee, Corey A. Siegel, Maria T. Abreu, Axel Dignaß, Laurent Peyrin-Biroulet, Theresa Hunter Gibble
article en
22 citations
Abstract
No abstract available for this paper.
Publication Tag
Inflammatory Bowel DiseasesVol. 31(7)
Institutions
Dartmouth–Hitchcock Medical Center (US), University of Miami (US), Inserm (FR), Eli Lilly (United States) (US), University of Calgary (CA), King's College London (GB), Kyorin University (JP), Guy's and St Thomas' NHS Foundation Trust (GB), Universitair Ziekenhuis Leuven (BE), McGill University Health Centre (CA), University of Washington Medical Center (US), University of Miami Health System (US), Clinique Hartmann (FR), Agaplesion Markus Hospital (DE), Amsterdam University Medical Centers (NL), Kitasato Institute Hospital (JP), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Kitasato University (JP), Icahn School of Medicine at Mount Sinai (US)